Strategic expansion SciSafe recently expanded its facility footprint to East Brunswick, NJ, signaling ongoing capacity growth and a readiness to serve more customers in the US biopharma space. This creates opportunities to upsell additional storage capacity, cross-sell warehousing services, and engage new regional clients with scalable storage solutions.

High compliance trust The company operates multiple certifications (ISO 20387, ISO 9001, CAP-BAP), and is FDA inspected with extensive SOP coverage, underscoring strong quality and regulatory alignment. This positions SciSafe as a preferred partner for regulated storage of sensitive biologics, cell therapies, and clinical trial materials, making it a compelling option for sponsors seeking compliant outsourcing.

End-to-end logistics In addition to storage, SciSafe offers sample transport services and freezers transport with a dedicated ULTemp fleet capable of moving materials from -86°C to -20°C and real-time monitoring. This enables a bundled offering for cold chain management, reducing supplier fragmentation for customers needing both storage and transport.

Diverse storage capabilities The ability to store a wide range of samples from DNA and vaccines to CAR-T and immunotherapy products across temperatures -196°C to +40°C, plus palletized storage options and ambient temp handling, provides cross-sell potential across multiple trial phases and product types for biopharma customers seeking a single, versatile partner.

Robust market positioning With a revenue range of 25–50 million and a recent high-profile acquisition signal from 1315 Capital, SciSafe sits between smaller niche providers and large CROs/CMOs. This positions it as an attractive target for mid-market sponsors looking for scalable, compliant storage and logistics at a favorable price-to-service balance.